Danaher Co. (NYSE:DHR) SVP Robert S. Lutz sold 15,000 shares of Danaher stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $103.80, for a total value of $1,557,000.00. Following the transaction, the senior vice president now owns 33,044 shares in the company, valued at $3,429,967.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of DHR traded down $0.36 during midday trading on Friday, hitting $104.39. The stock had a trading volume of 2,608,564 shares, compared to its average volume of 3,078,206. Danaher Co. has a twelve month low of $91.65 and a twelve month high of $110.13. The company has a market capitalization of $72.94 billion, a price-to-earnings ratio of 25.90, a P/E/G ratio of 2.00 and a beta of 1.04. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08.
Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, October 18th. The conglomerate reported $1.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.03. Danaher had a return on equity of 11.59% and a net margin of 14.07%. The firm had revenue of $4.85 billion for the quarter, compared to the consensus estimate of $4.80 billion. During the same quarter last year, the business posted $1.00 EPS. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. Sell-side analysts anticipate that Danaher Co. will post 4.51 earnings per share for the current fiscal year.
Several research firms have weighed in on DHR. Zacks Investment Research lowered Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th. Robert W. Baird reduced their target price on Danaher from $116.00 to $114.00 and set an “outperform” rating on the stock in a report on Friday, October 19th. Morgan Stanley lifted their target price on Danaher from $120.00 to $122.00 and gave the stock an “overweight” rating in a report on Friday, July 20th. Royal Bank of Canada lifted their target price on Danaher to $107.00 and gave the stock a “positive” rating in a report on Thursday, July 19th. They noted that the move was a valuation call. Finally, Bank of America set a $113.00 target price on Danaher and gave the stock a “buy” rating in a report on Thursday, July 19th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $112.14.
Several institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Principal Financial Group Inc. raised its stake in shares of Danaher by 2.2% in the 1st quarter. Principal Financial Group Inc. now owns 1,915,209 shares of the conglomerate’s stock valued at $187,519,000 after purchasing an additional 40,320 shares during the period. Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of Danaher by 17.9% in the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 11,186 shares of the conglomerate’s stock valued at $1,104,000 after acquiring an additional 1,700 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of Danaher by 11.0% in the second quarter. State of Alaska Department of Revenue now owns 94,234 shares of the conglomerate’s stock valued at $9,297,000 after acquiring an additional 9,310 shares during the last quarter. Trust Co. of Vermont increased its position in shares of Danaher by 1.8% in the second quarter. Trust Co. of Vermont now owns 33,329 shares of the conglomerate’s stock valued at $3,288,000 after acquiring an additional 601 shares during the last quarter. Finally, Xact Kapitalforvaltning AB increased its position in shares of Danaher by 4.2% in the second quarter. Xact Kapitalforvaltning AB now owns 121,458 shares of the conglomerate’s stock valued at $11,985,000 after acquiring an additional 4,862 shares during the last quarter. 76.80% of the stock is currently owned by hedge funds and other institutional investors.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Further Reading: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.